Fetal Diagnosis and Therapy
West Nile Virus during Pregnancy: A Case Study of Early Second Trimester Maternal InfectionSkupski D.W.a · Eglinton G.S.a · Fine A.D.b · Hayes E.B.c · O’Leary D.R.caThe New York Hospital Medical Center of Queens, Flushing, N.Y., bNew York City Department of Health and Mental Hygiene, New York, N.Y., and cNational Center for Infectious Diseases, Center for Disease Control and Prevention, Fort Collins, Colo., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: April 07, 2005
Accepted: June 29, 2005
Published online: April 06, 2006
Issue release date: April 2006
Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 0
ISSN: 1015-3837 (Print)
eISSN: 1421-9964 (Online)
For additional information: https://www.karger.com/FDT
Abstract
A woman who contracted West Nile virus (WNV) neuroinvasive illness during her second trimester subsequently elected to terminate her pregnancy due to concerns of possible adverse effects of WNV on her developing fetus. Consent was obtained to test maternal and post-mortem fetal tissues for WNV infection. Fetal blood, liver, kidneys, spleen, umbilicus and amniotic fluid were negative for WNV RNA by polymerase chain reaction and negative for WNV IgM antibodies by ELISA, indicating that in this case there was no evidence of WNV transmission to the fetus. Until further information regarding outcomes of WNV infection during pregnancy is available, pregnant women in areas where WNV is transmitted should take precautions to avoid mosquito bites. Women with WNV illness during pregnancy should undergo regular prenatal checkups including ultrasound examinations to assess fetal development, and healthcare providers should promptly report cases of WNV in pregnant women to their state or local health department or to CDC.
© 2006 S. Karger AG, Basel
Related Articles:
References
- Centers for Disease Control and Prevention: Intrauterine West Nile virus infection. New York, 2002. MMWR Morb Mortal Wkly Rep 2002;51:1135–1136.
-
Centers for Disease Control and Prevention: Case definitions for infectious conditions under public health surveillance: arboviral encephalitis or meningitis, 2001 (accessed June 30, 2003 at http://www.cdc.gov/epo/dphsi/casedef/encephalitiscurrent.htm).
- Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT: Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 2000;38:1823–1826.
- Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, Komar N, Panella NA, Allen BC, Volpe KE, Davis BS, Roehrig JT: Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol 2000;38:4066–4071.
-
Beaty BJ, Calisher CH, Shope RE: Arboviruses; in Lennette EH, Lenette DA, Lennette ET (eds): Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections, ed 7. Washington, American Public Health Association, 1995, pp 189–212.
- O’Leary DR, Marfin AA, Montgomery SP, Kipp AM, Lehman JA, Biggerstaff BJ, Elko VL, Collins PD, Jones JE, Campbell GL: The epidemic of West Nile virus in the United States, 2002. Vector-Borne Zoonotic Dis 2004;4:61–69.
- Hayes EB, O’Leary DR: West Nile virus infection: a pediatric perspective. Pediatrics 2004;113:1375–1381.
- Chapa JB, Ahn JT, DiGiovanni LM, Ismail MA: West Nile virus during pregnancy. Obstet Gynecol 2003;102:229–231.
- Koren G, Matsui D, Bailey B: DEET-based insect repellents: safety implications for children and pregnant and lactating women. Can Med Assoc J 2003;169:209–212.
-
Hayes EB, O’Leary DR, Rasmussen SA: Interim guidelines for the evaluation of infants born to mothers with West Nile virus infection during pregnancy. Centers for Disease Control and Prevention Morb Mortal Wkly Rep 2004;53:154–157.
Article / Publication Details
Received: April 07, 2005
Accepted: June 29, 2005
Published online: April 06, 2006
Issue release date: April 2006
Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 0
ISSN: 1015-3837 (Print)
eISSN: 1421-9964 (Online)
For additional information: https://www.karger.com/FDT
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
